Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov:345:103964.
doi: 10.1016/j.cellimm.2019.103964. Epub 2019 Aug 13.

The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma

Daniel Feinberg  1 , Barry Paul  1 , Yubin Kang  2
Affiliations
Review

The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma

Daniel Feinberg et al. Cell Immunol. 2019 Nov.

Abstract

A cure for multiple myeloma (MM), a malignancy of plasma cells, remains elusive. Nearly all myeloma patients will eventually relapse and develop resistance to currently available treatments. There is an unmet medical need to develop novel and effective therapies that can induce sustained responses. Early phase clinical trials using chimeric antigen receptor (CAR) T cell therapy have shown great promise in the treatment of relapsed and/or refractory MM. In this review article, we provide an overview of the CAR constructs, the gene transfer vector systems, and approaches for T cell activation and expansion. We then summarize the outcomes of several early phase clinical trials of CAR T cell therapy in MM and the novel CAR T targets that are under development. Finally, we explore the potential mechanisms that result in disease relapse after CAR T therapy and propose future directions in CAR T therapy in MM.

Keywords: Chimeric antigen receptor; Efficacy; Multiple myeloma; Toxicities; Treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing conflicts of interest.

Figures

Figure 1:
Figure 1:
CAR T construct
See this image and copyright information in PMC

References

    1. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P, Management of treatment-emergent peripheral neuropathy in multiple myeloma, Leukemia, 26 (2012) 595–608. - PubMed
    1. Latov N, Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies, Annals of neurology, 37 Suppl 1 (1995) S32–42. - PubMed
    1. Batuman V, The Pathogenesis of Acute Kidney Impairment in Patients With Multiple Myeloma, Advances in Chronic Kidney Disease, 19 (2012) 282–286. - PubMed
    1. Rajkumar SV, Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management, American journal of hematology, 91 (2016) 719–734. - PMC - PubMed
    1. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline, Journal of Clinical Oncology, 37 (2019) 1228–1263. - PubMed

Publication types

MeSH terms

Substances